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1. Introduction 
The resurgence of tuberculosis is ascribed to several factors such as: large scale migration, 
co-infection with immunodeficiency virus, and the emergence of Mycobacterium tuberculosis 
drug-resistant strains. 
Drug-resistant tuberculosis is a growing global health problem. This has led to an increased 
urgency to understand the molecular mechanisms of drug action and drug resistance, which 
could give significant insight into the development of new compounds. New molecules 
should be useful to fight both drug-susceptible as well as drug-resistant strains (Caminero et 
al., 2010). 
It is noteworthy that the development of drug-resistant M. tuberculosis strains is essentially 
favored by an inappropriate drug prescription of physicians and irregular intake of the 
drugs by patients (Goldman et al., 2007). Bacterial resistance to antibiotics typically involves 
drug inactivation or modification, target alteration, diminished drug accumulation 
associated with decrease in permeability and/or increase in efflux. Other resistance 
mechanisms include inhibition of the activation of pro-drugs into active drugs. Bacterial 
resistance may be an intrinsic feature of an organism, or may result from spontaneous 
mutations or the acquisition of exogenous resistance genes. As M. tuberculosis does not 
possess plasmids and horizontal gene transfer is thought to be rare, all resistances appear to 
emerge through mutations in chromosomal genes (Gillespie, 2007). Chromosomal 
alterations that result in resistance to antitubercular drugs may be associated with a fitness 
cost. Based on work in experimental models and from observations in clinical drug resistant 
isolates, it has been observed that among the various resistance mutations that appear with 
similar rates, those associated with the least fitness cost are selected in the population 
(Böttger and Springer, 2008). Consequently, to reduce the rate of spread of resistant bacteria 
it is necessary to identify targets for which the resistance mechanisms have the most 
negative effects on bacterial fitness. M. tuberculosis shows a high degree of intrinsic 
resistance to several antibiotics and chemotherapeutic agents attributed to the low 
permeability of its cell wall, in particular because of its specific lipid-rich composition and 
structure (Jarlier and Nikaido, 1994). However, some reports have suggested that efflux 
pumps may also be involved (De Rossi et al., 2006).  The balance between the drug transport 
into the cell and drug efflux is not yet clearly understood, and further studies are required in 
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mycobacteria (De Rossi et al., 2006). The development of mycobacterial resistance to 
antibiotics has co-evolved over time with the discovery of antitubercular drugs. Indeed, M. 
tuberculosis mutants resistant to any single drug were identified and most of them 
characterized.  
Drugs utilized to treat tuberculosis are classified into first-line (isoniazid, rifampicin, 
pyrazinamide, and ethambutol) and second-line agents (quinolones, aminoglycosides, 
linezolid, ethionamide, and D-cycloserine).  The commonly used antitubercular regimen is 
based on four first-line agents: isoniazid, rifampin, pyrazinamide, and ethambutol, for the 
first two months, followed by rifampin and isoniazid treatment for a further four months, as 
recommended by the World Health Organization.  
Strains of M. tuberculosis that are resistant to both isoniazid and rifampicin, with or without 
resistance to other drugs, named multidrug-resistant strains (MDR-TB), require a further 
two years of treatment with second-line drugs such as: quinolones, aminoglycosides, 
ethionamide, D-cycloserine and basic peptides. The emergence of Extensively drug-resistant 
tuberculosis (XDR-TB), caused by MDR-strains also resistant to two major second-line 
agents (aminoglycosides and fluoroquinolones), greatly alarmed the World Health 
Organization. These resistant strains have been identified in all regions of the World, most 
often in Asia and countries of the former Soviet Union (Caminero et al., 2010). 
Beside the problem of XDR-TB cases, which remains unresolved in many regions of the 
World, new totally drug-resistant strains (TDR), or super XDR-TB isolates, have been 
reported. M. tuberculosis isolates are defined TDR if they are resistant to all first-line 
(isoniazid, rifampicin, streptomycin, ethambutol, and pyrazinamide) and second-line drugs 
(quinolones, aminoglycosides, linezolid, ethionamide, and D-cycloserine) (Velayati et al., 
2009). Generally, the spectrum of resistance reflects the drugs that the patients have used 
and the way in which therapy was controlled. 
The treatment of tuberculosis becomes more complicated as the antibiotic resistance profile 
of M. tuberculosis broadens. MDR and XDR tuberculosis are generally thought to have high 
mortality rates; for TDR-TB there are no drugs available. In fact, with the exception of the 
fluoroquinolones, no new antitubercular drug has been introduced in therapy in the past 45 
years (Caminero et al., 2010). 
In recent years, the increasing concern for drug resistance has hurried the need for the 
development of new control measures. At present, the identification of new drugs and new 
cellular targets is prioritised (Riccardi et al., 2009). 
Presently, ten compounds with antitubercular activity have entered clinical trials (Lenaerts 
et al., 2008; Riccardi et al., 2009), while other promising ones are still in pre-clinical 
development (Lienhardt et al., 2010). This has been prompted since the availability of the M. 
tuberculosis genome sequence (Cole et al., 1998), when several Laboratories in the World 
have utilized the genomic data to identify and validate targets as starting point for the 
development of new antitubercular drugs. Genomic sequence information allows also the 
use of comparative genomic analysis to identify new potential targets, and provides some 
assurance against mammalian toxicity if homologous proteins are absent from mammalian 
sequence databases. Sequence similarities can also give useful hints on putative protein 
functions. Transposon mutagenesis and signature-tagged mutagenesis have been used to 
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identify essential M. tuberculosis genes (Lamichhane et al., 2005; Sassetti et al., 2003; Sassetti 
and Rubin, 2003). The functional categories to which these genes belong are: lipid 
metabolism; carbohydrate, amino acid, inorganic ion and nucleotide transport and 
metabolism; energy production and conversion; secretion; cell envelope biosynthesis; cell 
division; DNA replication, recombination and repair; transcription and translation; post-
translational modification; chaperones; coenzyme metabolism; signal transduction. These 
essential mycobacterial genes could encode good targets for tuberculosis drug development. 
Another intriguing field of research concerns the metabolism of several molecules, 
important for bacterial survival.  
The use of protein structure data to design molecules, that are most likely to interact with 
inhibitable proteins, constitute another field of research, aimed to create novel classes of ad 
hoc inhibitors able to interact with a bacterial protein and block its function. Thanks to the 
efforts of the Tuberculosis Structural Genomics, more than 260 X-ray crystal structures of 
interesting proteins have been completed (Chim et al., 2011). The availability of these 
structures provides the opportunity to carry out virtual screenings for drug discovery. 
Virtual screening can be used to identify compounds that are consistent with a 
pharmacophore model, without considering the target/s or to develop inhibitors of a 
protein, on a known three-dimensional structure. The pharmaceutical industry has favoured 
this target-based approach to drug discovery. While successful in some cases, this high 
throughput screening approach has failed miserably in the antibacterial discovery area 
(Payne et al., 2007; Fischbach and Walsh, 2009). Also in our own experience, target-based 
screens generate hits but these usually fail to show useful minimum inhibitory 
concentrations against M. tuberculosis.  The reasons for this collective failure remain unclear 
but may include the inability of many synthetic compounds to enter bacteria and find their 
target, the presence of efflux systems or other innate resistance mechanisms.  
For tuberculosis drug discovery the research process has often begun either via phenotypic 
screening of compound libraries against M. tuberculosis or a surrogate organism, such as 
Mycobacterium smegmatis or Mycobacterium bovis BCG growing in vitro culture, or against a 
target of interest. This effort has created the pipeline of new candidate drugs at various 
stages of preclinical and early clinical evaluations (Lenaerts et al., 2008; Lienhardt et al., 
2010; Riccardi et al., 2009).  
In the last five years, within the European Community network, the “New Medicines for 
Tuberculosis” consortium (to which our laboratory belongs) has been working to 
successfully develop new drugs for the treatment of tuberculosis through an integrated 
approach (http://www.sciprom.ch/nm4tb/). The group has just obtained new funding 
from the European Community with the project “More Medicines for Tuberculosis”. 
Development and implementation of novel enabling technologies required for drug 
development, target validation in well-established areas such as the central metabolism, cell 
wall and nucleic acid synthesis, in addition to more challenging yet highly innovative 
topics, are the major expected results of the network. Within this project, a new effective 
antimycobacterial agent, belonging to the nitrobenzothiazinone class and with a minimal 
inhibitory concentration of 1 ng/ml, that quickly kills M. tuberculosis in vitro, ex vivo and in 
murine models of tuberculosis, has been discovered (Makarov et al., 2009). The lead 
compound benzothiazin-4-one (BTZ038) has a single chiral center, and both enantiomers, 
BTZ043 (S) and BTZ044 (R), were found to be equipotent in vitro. This drug is also active 
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against extensively- and  multi-drug resistant clinical isolates, and it is in the pre-clinical 
trial phase. A huge amount of genetic and biochemical data indicates that DprE1 is the 
target of benzothiazinones (Makarov et al., 2009). DprE1 enzyme works in concert with 
DprE2 to catalyse the epimerization of decaprenyl-D-ribose to decaprenyl-D-arabinose in 
the biosynthesis of arabinogalactan, a fundamental component of mycobacterial cell wall 
(Wolucka, 2008). The DprE1 enzyme thus represents a proven vulnerable antimycobacterial 
drug target that could turn out magic for tuberculosis treatment (Manina et al., 2010b). In 
order to monitor the potential development of benzothiazinone-resistance, a total of 240 
sensitive and MDR clinical isolates from four European hospitals were surveyed for the 
presence of mutations in the dprE1 gene and for benzothiazinone susceptibility. All 240 
strains were susceptible, thus establishing the baseline prior to the introduction of BTZ043 in 
clinical trials (Pasca et al., 2010).  
Moreover, it has been shown that DprE1 is the target also of another class of very promising 
drugs, the dinitrobenzamides (Christophe et al., 2009). These compounds are active against 
mycobacteria and non toxic for the host cell, and they have been identified through the 
screening of chemicals which interfere with M. tuberculosis replication within macrophages 
(Christophe et al., 2009). In particular, the dinitrobenzamide derivatives were found to be 
highly active against M. tuberculosis. Two compounds were selected, N-(2-(4-
methoxyphenoxy) ethyl)-3,5-dinitrobenzamide and N-(2-(benzyloxy) ethyl)-3,5-
dinitrobenzamide, for further studies and target identification. Analysis of the broad 
antimicrobial spectrum was undertaken and revealed that the effect of these 
dinitrobenzamide derivatives has the most potent activity observed against mycobacteria 
with a minimal inhibitory concentration of 75 ng/ml. Of particular importance, these 
compounds were also highly active against MDR- and XDR-TB clinical isolates. In order to 
gain insight into the possible targets of dinitrobenzamides, the effect of these chemicals on 
the lipid composition of the cell envelope of M. tuberculosis was investigated; results showed 
that they affected the synthesis of the arabinan domains of arabinogalactan and 
lipoarabinomannan. In particular, analyses revealed complete inhibition of decaprenyl-
phospho-arabinose formation in the dinitrobenzamide-treated extract concurrent with the 
accumulation of decaprenyl-phospho-ribose, indicating that the target of both 
dinitrobenzamide inhibitors is probably the heteromeric decaprenyl-phospho-ribose 2’ 
epimerase. 
Our group also identified and characterized a novel resistance mechanism to 
benzothiazinones in M. smegmatis (Manina et al., 2010a), and this mechanism was confirmed 
also for dinitrobenzamides (M.R. Pasca, personal communication). The over-expression of 
the nitroreductase NfnB led to the inactivation of the drug by reduction of a critical nitro-
group to an amino-group. The direct involvement of NfnB in the inactivation of the lead 
compound BTZ043 was demonstrated by enzymology, microbiological assays and gene 
knockout experiments. The crystal structure of NfnB and docking analysis of NfnB-
benzothiazinones have been performed in order to understand their interaction and the 
mechanism of nitroreduction (Manina et al., 2010a). Although M. tuberculosis seems to lack 
nitroreductases able to inactivate these drugs, our findings are valuable for the design of 
new benzothiazinones, which may be more effective in vivo. 
In conclusion  many approaches are utilized to fight tuberculosis. The two principal research 
routes to find out new antibacterial molecules and novel bacterial targets are from drug to 
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target and from target to drug. Until now the first one appears to be the most easily 
attainable, leading to the discovery of new molecules which are currently in clinical trials 
and the last published benzothiazinones and dinitrobenzamides. However, we should 
remember that there is a high attrition rate during clinical trials before a candidate is 
approved for human use and resistance to new compounds will eventually arise, so drug 
discovery efforts should be intensified. 
2. Benzothiazinones 
The class of Benzothiazinones (BTZs) comprises a series of sulfur-containing heterocycle 
compounds with antibacterial and antifungal activity (Makarov et al., 2006). One of BTZs, 2-
[2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3 benzothiazin-
4-one (BTZ038), was selected for further studies (Figure 1; Makarov et al., 2009).  
 
Fig. 1. Chemical structure of the lead compound BTZ038. 
This compound was synthesized in seven steps with a yield of 36%. Structure activity 
relationship work showed that the sulfur atom and the nitro group at positions 1 and 8, 
respectively, were critical for activity. BTZ038 has a single chiral center, and both 
enantiomers, BTZ043 (S) and BTZ044 (R), were found to be equipotent in vitro.  
The minimal inhibitory concentrations (MICs) of a variety of BTZs against different 
mycobacteria were very low, ranging from ~0.1 to 80 ng/ml for fast growers and from 1 to 
30 ng/ml for members of the M. tuberculosis complex. The MIC of BTZ043 against M. 
tuberculosis H37Rv and M. smegmatis were 1 ng/ml (2.3 nM) and 4 ng/ml (9.2 nM), 
respectively (Makarov et al., 2009), indicating that this compound is more potent than 
isoniazid (500 ng/ml). BTZ043 displayed similar activity against all clinical isolates of M. 
tuberculosis that were tested, including MDR and XDR strains (Makarov et al., 2009). 
BTZ043 is bactericidal, reducing viability in vitro by more than 1000-fold in under 72 hours.  
The uptake, intracellular killing, and potential cytotoxicity of BTZ compounds in an ex vivo 
model using a high-content screening approach (Fenistein et al., 2008), in order to monitor  
macrophages infected with M. tuberculosis expressing the green fluorescent protein, were 
determined. Macrophages treated with BTZ043 were protected as compared with those 
treated with the negative controls (Makarov et al., 2009). 
The in vivo efficacy of BTZ043 was assessed 4 weeks after a low-dose aerosol infection of 
BALB/c mice in the chronic model of tuberculosis. Four weeks of treatment with BTZ043 
reduced the bacterial burden in the lungs and spleens by 1 and 2 logs, respectively, at the 
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concentrations used. Additional results suggested that BTZ efficacy is time- rather than 
dose-dependent (Makarov et al., 2009). 
To find the target for BTZ, two independent genetic approaches were employed. Firstly, 
cosmids bearing DNA from M. smegmatis that confer increased resistance on M. smegmatis 
were identified and the region responsible was pinpointed by subcloning. This approach 
revealed that the MSMEG_6382 gene of M. smegmatis or its M. tuberculosis ortholog, Rv3790, 
mediated increased BTZ resistance. Secondly, M. smegmatis, M. bovis BCG, and M. tuberculosis 
mutants with a high-level of BTZ resistance were isolated and characterized. All these resistant 
mutants harbored missense mutations in the same gene (Makarov et al., 2009).  
Biochemical studies showed that Rv3790 and the neighboring gene Rv3791 code for proteins 
that act in concert to catalyze the epimerization of decaprenylphosphoryl-D-ribose (DPR) to 
decaprenylphosphoryl-D-arabinose (DPA) (Mikusova et al., 2005), a precursor for arabinan 
synthesis without which a complete mycobacterial cell wall cannot be produced (see the 
paragraph below).  
In all of the drug-resistant mutants we examined, the same codon of Rv3790 (or DprE1) was 
affected: cysteine at position 387 was replaced by serine or glycine codons, respectively. The 
BTZ resistance–determining region of dprE1 was highly conserved in orthologous genes 
from various Actinobacteria, except that in a few cases cysteine (387 codon) was replaced by 
serine or alanine. The corresponding bacteria, Mycobacterium avium and Mycobacterium 
aurum, were found to be naturally resistant to BTZ thus supporting the identification of 
DprE1 as the BTZ target (Makarov et al., 2009; Figure 2).  
Further corroboration was obtained biochemically by using membrane preparations from 
M. smegmatis to catalyze the epimerization reaction from radiolabeled DPR precursor, which 
was produced in situ from 5-phosphoribose diphosphate (Mikusova et al., 2005), in the 
presence or absence of BTZ. Addition of BTZ abolished the production of DPA from DPR.  
The reaction requires both DprE1 and DprE2. Furthermore, when the highly BTZ-resistant 
mutant of M. bovis BCG, or M. smegmatis were used as sources of enzymes, epimerization 
was no longer subjected to inhibition, thereby confirming identification of the BTZ target 
(Makarov et al., 2009). 
 
Fig. 2. Multiple alignment of the BTZ resistance–determining region in orthologs of 
dprE1 from various actinobacteria by ClustalW. The cysteine (or correspondent amino 
acid) involved in the BTZ binding is highlighted in grey. 
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In order to monitor the potential development of BTZ resistance, a total of 240 sensitive and 
multidrug-resistant M. tuberculosis clinical isolates from four European hospitals were 
surveyed for the presence of mutations in the dprE1 gene and for BTZ susceptibility (Pasca 
et al., 2010). 
The pharmaceutical industry usually estimates the likelihood of the development of 
resistance against a new drug by focusing on the mutation resistance rate, on the 
assumption that this rate is a major determinant of resistance development in clinical 
settings (Andersson, 2006). Therefore, drug targets for which the resistance mechanisms 
have the most negative effect on fitness are expected to show a low resistance development 
rate (Andersson, 2006). It is noteworthy that in vitro M. tuberculosis BTZ-resistant mutants 
were rare, arising at a frequency of 10-8 (Makarov et al., 2009) and they have not a good 
fitness (M. R. Pasca, unpublished results). 
The M. tuberculosis clinical isolates (including MDR- and XDR-TB strains) from four 
different European hospitals were screened for mutations in the Cys387 codon of dprE1 and 
for BTZ sensitivity. Seventy-eight M. tuberculosis clinical isolates came from the National 
Institute for Infectious Diseases (INMI) “L. Spallanzani” hospital in Rome, Italy; 118 strains 
were isolated at the Sondalo Division of the Valtellina and Valchiavenna, Italy, hospital 
authority; 32 clinical isolates were from the “Ambroise Paré” Hospital in Boulogne-
Billancourt, France; and 12 strains were isolated at the “Central Institute of Tuberculosis” in 
Moscow, Russia. All strains were isolated between 2003 and 2009 and 1 was an XDR strain 
and 38 (15.8%) had an MDR phenotype. Moreover, 35 MDR strains were resistant to other 
first- and second-line drugs and they were sensitive to only a few drugs. Some M. 
tuberculosis clinical isolates were resistant to one or more drugs but did not meet the MDR 
definition (24.6%). Seven M. tuberculosis clinical strains were isolated from HIV-positive 
patients. The dprE1 gene was amplified by PCR and sequenced from all clinical isolates. 
None of the M. tuberculosis isolates had mutations in the dprE1 gene, and hence, these 
isolates were presumably sensitive to BTZ (Pasca et al., 2010). This result confirms that BTZ 
resistance mutations are not present in the strains of M. tuberculosis currently circulating. 
From these results, it is reasonable to hypothesize that the cysteine residue has a 
fundamental role in BTZ sensitivity, possibly in drug binding. 
To confirm this hypothesis, we showed that all the M. tuberculosis clinical isolates were 
sensitive to BTZ043, with values ranging from 0.75 to 30 ng/ml. This result confirms that 
BTZ043 is very active against both sensitive and resistant strains of M. tuberculosis, including 
MDR and XDR strains (Pasca et al., 2010). 
These results have very important implications for future clinical trials. Specifically, it will 
be possible to perform an easy and rapid diagnostic test for BTZ resistance in clinical isolates 
simply by sequencing the dprE1 gene around the Cys387 codon or by using a real time-PCR 
assay, thus bypassing the need for systematic MIC determination. 
Given the previous results, the BTZs have been shown to be a new class of potent 
antimycobacterial agents. 
Other information about the binding between the BTZs and their target came from Trefzer 
and collaborators that demonstrated that BTZs are activated in the bacterium by reduction 
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of an essential nitro group to a nitroso derivative, which then specifically reacts with a 
cysteine residue in the active site of DprE1 (Trefzer et al., 2010).  
As early metabolic studies with bacteria or mice indicated that the BTZ nitro group could be 
reduced to an amino group, and as many antitubercular drugs are prodrugs that require 
activation by M. tuberculosis, the S and R enantiomers of the amino derivatives and the likely 
hydroxylamine intermediate were synthesized and tested for antimycobacterial activity in 
vitro. The amino and hydroxylamine derivatives were substantially less active (500- to 5000-
fold) respect to the nitro form (Makarov et al., 2009). 
In this context, another novel resistance mechanism to BTZs was described in M. smegmatis 
(Manina et al., 2010a). The over-expression of the nitroreductase NfnB leads to the 
inactivation of the drug by reduction of a critical nitro group to an amino group (Figure 3).  
 
Fig. 3. Nitroreduction of BTZ nitro form in amino form by NfnB nitroreductase. 
The direct involvement of NfnB in the inactivation of the lead compound BTZ043 was 
demonstrated by enzymology, microbiological assays and gene knockout experiments. 
M. smegmatis resistant mutants which showed a low level of BTZ resistance (16X-MIC) were 
isolated. One of these mutants harbored neither mutations in MSMEG_6382 nor in 
MSMEG_6385, the genes orthologous to M. tuberculosis dprE1 and dprE2, respectively. In 
order to identify the gene responsible for the BTZ resistance phenotype, this mutant was 
transformed with a wild-type M. smegmatis cosmid library, and a selection for sensitivity to 
BTZ043 was carried out. A transformant colony characterized by a resistance decrease from 
16X-MIC to 2X-MIC was isolated, and the correspondent cosmid responsible for restoration 
of BTZ043 sensitivity, was isolated and partially sequenced. Subcloning experiments of the 
cosmid were then performed and this led to the identification of a fragment responsible for 
the resistance containing the MSMEG_6503 gene, coding for a putative transcriptional 
regulator from the TetR family, and the MSMEG_6505 gene, coding for NfnB enzyme due to 
its 35% sequence identity to the E. coli NfnB/NfsB nitroreductase. The sequence analysis 
revealed no mutations in the nfnB gene, but a point mutation in MSMEG_6503. This 
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mutation led to the substitution of leucine at position 137 by proline, leading to the 
hypothesis that the resistance of this mutant could be due to a defective repressor 
(MSMEG_6503), possibly causing over-expression of NfnB and, consequently, the reduction 
of the BTZ nitro-molecule to its less active amino-derivative (Manina et al., 2010a). 
Consistent with this hypothesis, the MIC of BTZ045, the amino derivative of BTZ043, for M. 
smegmatis was already known to be 0.5 g/ml versus 4–8 ng/ml of the original nitro 
compound (Makarov et al., 2009). 
Moreover, 14 other spontaneous mutants, showing different levels of resistance (8–32X-
MIC), were found to carry mutations in the MSMEG_6503 gene, including deletions and 
insertions. All the mutant strains were predicted to produce a truncated form of the protein. 
One of these mutants presented a mutation in the hypothetical repressor binding site 
(Manina et al., 2010a). 
In order to verify the role of MSMEG_6503 in nfnB regulation, MSMEG_6503 proteins from 
M. smegmatis wild-type and from one of the mutants were purified and used in DNA 
binding assays.  MSMEG_6503 from M. smegmatis wild-type  strain was able to bind and 
efficiently retard the MSMEG_6503-nfnB intergenic region, while the mutant protein bound 
this region less efficiently (Manina et al., 2010a). 
High levels of nfnB expression were detected by Real-Time PCR in the M. smegmatis BTZ 
resistant mutants (Manina et al., 2010a). 
To further confirm the direct role of NfnB in the BTZ resistance, an in-frame unmarked 
deletion was created in the nfnB gene and the nfnB strain was sensitive to BTZ (Manina et 
al., 2010a). 
Both wild-type M. smegmatis and one of the resistant mutants were evaluated for their 
ability to convert the nitro-compound to the amino-derivative, by high-pressure liquid 
chromatography (HPLC) analysis of culture media. The mutant transforms the nitro- to the 
amino-compound more efficiently and more rapidly compared with M. smegmatis wild-type 
strain (Manina et al., 2010a). 
In order to assess the activity of the purified NfnB protein towards BTZ043, an indirect 
evaluation was initially performed, using an assay in which BTZ043 blocks the 
epimerization of DPR to DPA (Makarov et al., 2009). Recombinant NfnB enzyme was thus 
added to the assay mixtures to monitor DPA synthesis. When BTZ043 was pretreated with 
purified NfnB prior to addition to the reaction mixture, DPA was still formed, most likely 
due to the conversion of the active drug (BTZ043) to its inactive amino form (Manina et al., 
2010a). 
M. tuberculosis most probably lacks enzymes able to inactivate BTZ043 either in aerobic or 
anaerobic environment, consistent with the low MIC values of BTZ043 in M. tuberculosis and 
the fact that all the BTZ-resistant mutants isolated so far in this species harbored mutations 
in the target gene dprE1 (Manina et al., 2010a). 
The crystal structure of NfnB was determined at 1.75 Å resolution. The structure of NfnB in 
complex with NADPH was obtained by the prior addition of the cofactor during 
crystallization, and was refined in the same crystallographic space group at 1.80 Å 
resolution (Manina et al., 2010a). 
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It was shown that a common amino acid stretch between NfnB and DprE1 is likely to be 
essential for the interaction with BTZ. An amino acid sequence alignment shows a common 
amino acid stretch of 30 amino acids between NfnB (residues 86–115) and DprE1 (residues 
386–417), displaying 46% sequence identity (59% similarity). It is noteworthy that this amino 
acid stretch is located at the C-terminal end of DprE1, the same region in which spontaneous 
mutations conferring resistance to BTZ were identified (Makarov et al., 2009), suggesting 
that this polypeptide portion might also play a key role in defining the relative specificity of 
NfnB towards the nitromolecules from the BTZ class. Docking analysis of NfnB-BTZ was 
performed in order to understand their interaction and the mechanism of nitroreduction 
(Manina et al., 2010a). 
However, it has also been observed that the nitro-BTZ compounds are transformed into the 
corresponding amino-derivatives not only in M. smegmatis cultures overexpressing NfnB, 
but also in blood and urine from treated mice (V. Makarov, unpublished data), strongly 
suggesting that one or more nitroreductases, either mammalian or from the intestinal 
microbial flora, could carry out such a conversion. Indeed, it is well known that 
nitroaromatic compounds can be converted into their metabolites in the intestine, by the 
action of several microbial nitroreductases (Roldán et al., 2008). 
Although M. tuberculosis seems to lack nitroreductases able to inactivate these drugs, this 
finding is useful for the design of new BTZ molecules or new antitubercular drugs, which 
may be more effective in vivo. 
3. Dinitrobenzamides 
Another new class of potent antitubercular drugs, the dinitrobenzamide derivatives (DNBs) 
(Figure 4), was identified through a screening of chemicals which interfere with M. 
tuberculosis replication within macrophages (Christophe et al., 2009). The most active 
compounds among DNBs exhibited substitutions of the benzene moiety with a nitro group 
at positions 3 and 5. The two major compounds from this series, [N-(2-(4-methoxyphenoxy) 
ethyl)-3,5-dinitrobenzamide] and [N-(2-(benzyloxy) ethyl)-3,5-dinitrobenzamide], named 
DNB1 and DNB2 respectively, were also highly active against M. tuberculosis MDR and XDR 
strains (Christophe et al., 2009; Figure 4). 
To find the DNB derivatives, a new phenotypic cell-based assay for high throughput 
screening of chemical compounds that interfere with the replication of M. tuberculosis within 
macrophages was developed. This assay is based on the use of automated confocal 
fluorescent microscopy to monitor intracellular growth of green fluorescent protein-
expressing M. tuberculosis H37Rv in Raw264.7 macrophages (Christophe et al., 2009). 
A screening of a library of 56,984 small molecules led to the identification of 135 active 
compounds with potent intracellular anti-mycobacterial efficacy and no host cell toxicity. 
Among these, the DNB derivatives showed high activity against M. tuberculosis. The assay 
was set-up for the high throughput screening of large chemical libraries in 384-well format. 
To set up the optimal conditions of M. tuberculosis infection, Raw264.7 macrophages were 
first infected with mycobacteria that constitutively express green fluorescent protein using 
different multiplicities of infection followed by kinetic analysis of intracellular bacterial 
growth. Confocal images of live samples were acquired using an automated confocal 
microscope (OperaTM) over 7 days (Christophe et al., 2009). 
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Fig. 4. Chemical structure of dinitrobenzamide compounds. R1 can be either a nitro (-NO2), 
an amino (-NH2), a hydroxylamine (-NHOH) or a hydrogen (-H) group, whereas R2 stands 
for different aromatic substituents. 
This chemical library was first screened at a single concentration. 486 fully active hits were 
then confirmed by means of serial dilution experiments. More than one quarter of the hits 
(135 hits) had an MIC less than 5 mM, and 8% had a MIC below 1 mM, which is equivalent 
to that of isoniazid (Christophe et al., 2009).  
The largest cluster had 69 members with an isonicotinohydrazide moiety similar to that of 
isoniazid, used as a positive reference in the assay. The second largest cluster of 24 
derivatives shares a common benzamide scaffold. A series of related derivatives was 
synthesized for further studies. To identify the chemical substituents necessary for 
benzamide antibacterial activity, over 155 additional derivatives were synthesized and their 
structure-activity relationship was analyzed using both intracellular assay and the in vitro 
growth assay. The most potent compounds exhibited substitutions of the benzene moiety 
with a nitro group at positions 3 and 5. The reduction of one nitro- to hydroxylamine and 
amino groups led to totally inactive compounds. In contrast, derivatives with an N-
substitution by benzyloxy-ethyl or by phenoxy-ethyl showed enhanced activity with an MIC 
below 0.2 mM. More importantly, cyclic-benzamides had an MIC below 80 nM in the in vitro 
assay. Moreover, substitution of the benzyloxy moiety by a chlorine- or fluorine atoms at 
position 3 led to increased potency in both assays in contrast to carboxyl substitutions. Two 
compounds, N-(2-(4-methoxyphenoxy) ethyl)-3,5-dinitrobenzamide (DNB1) and N-(2-
(benzyloxy) ethyl)-3,5-dinitrobenzamide (DNB2) were selected for the characterization. No 
cell toxicity was noted for these compounds using conventional cytotoxicity assays of 
uninfected cells, indicating that this assay can predict the cytotoxicity. Analysis of the broad 
antimicrobial spectrum revealed that the effect of these dinitrobenzamide derivatives was 
mainly restricted to Actinomycetes. Of particular importance, DNB1 and DNB2 were also 
highly active against MDR and XDR clinical isolates. The bactericidal effect on M. 
tuberculosis of DNB1 and DNB2 was found to be time-dependent and to require several days 
to reach bacterial clearance, implying that they could interfere with de novo mycobacterial 
component biosynthesis. This is further corroborated by the fact that the DNB compounds 
lost their activity in a non-replicating M. tuberculosis system (Christophe et al., 2009).  
In a preliminary experiment using the acute mouse model of M. tuberculosis, a one log 
reduction of the colony forming unit in the lungs of DNB treated animals compared to non-
www.intechopen.com
 
Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance 
 
284 
treated controls was observed after a three week daily treatment with 30 mg/kg/day 
following an intranasal infection.  
To gain insight into the possible targets of dinitrobenzamides, the effect of DNB1 and DNB2 
on the lipid composition of the cell envelope of M. tuberculosis was investigated; no effects 
on the biosynthesis of fatty acids, mycolic acids and/or other lipids were noted. By contrast, 
DNB1 and DNB2 showed a clear-cut effect on the synthesis of the arabinan domains of 
arabinogalactan and lipoarabinomannan. DPA is the only known arabinofuranose (Araf) 
donor in the biogenesis of arabinogalactan and lipoarabinomannan in mycobacteria and is 
thus an essential precursor (Wolucka, 2008). The effects of DNB in the inhibition of the 
synthesis of DPA were tested. Analyses revealed complete inhibition of DPA formation in 
the DNB-treated extracts, concurrent with the accumulation of DPR, indicating that the 
target of DNB inhibitors could be the heteromeric decaprenylphospho-ribose epimerase 
encoded by the dprE1/dprE2 genes in M. tuberculosis H37Rv, the same target of 
benzothiazinones (Christophe et al., 2009; Makarov et al., 2009). Moreover BTZ resistant 
mutants of M. smegmatis and M. bovis BCG having a mutation in dprE1 gene, were also 
resistant to DNB inhibitors. 
Recently it has been demonstrated that the DNB and the BTZ have not only the same target, 
but also the same mechanisms of resistance (M.R. Pasca, unpublished data). 
4. The decaprenyl-phosphoribose 2’-epimerase  
Mycobacteria cell envelope is a peculiar characteristic of these microorganisms. It forms an 
efficient permeability barrier, playing a crucial role in intrinsic drug resistance as well as in 
macrophage survival under stress conditions. Several fundamental antitubercular drugs, 
such as isoniazid and ethambutol, target enzymes involved in some specific cell-wall 
biosynthetic pathways (Barry et al., 2007). Furthermore the mycobacterial  cell envelope is 
still considered an outstanding cellular source for target discovery. 
The mycobacterial cell envelope is composed of three main portions. From the external side 
towards the cytoplasmic membrane we find: a highly impermeable layer of mycolic acids 
(long-chain (C70–C90) -branched, -hydroxy fatty acids), the complex polysaccharide 
arabinogalactan, and a peptidoglycan layer. Arabinogalactan is covalently attached to 
peptidoglycan by a phosphodiester linkage and is esterified by mycolic acids. The entire 
complex is named mycolyl-arabinogalactan–peptidoglycan (Alderwick et al., 2007), and 
represents a strong protective barrier for the pathogen. This complex also keeps a dynamic 
trait, useful for facing different environmental conditions. Chemical analysis of the cell 
envelope composition has also revealed the presence of diverse noncovalently bound lipids 
(such as phosphatidyl-myo-inositol mannosides), lipopolysaccharides (such as 
lipoarabinomannans), mannose-capped lipoarabinomannans, poly-L-glutamate–glutamine 
polymers, enzymes and other proteins. In slow-growing mycobacterial species, such as M. 
tuberculosis, proteins and polysaccharides are present in the outermost stratum known as the 
capsule (Umesiri et al., 2010). 
Synthesis of arabinan domain of arabinogalactan derives from sequential additions of Araf 
residues to the galactan domain, while lipoarabinogalactan originates from the addition of 
Araf units on the mannan domain by specialized arabinosyltransferases (Wolucka, 2008). 
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These enzymes utilize the unusual sugar decaprenylphosphoryl-D-arabinose (DPA, Figure 
5) as the only donor of Araf residues in both mycobacteria and corynebacteria (Meniche et 
al., 2008). It is noteworthy that without DPA, a complete mycobacterial cell wall cannot be 
produced. DPA is synthesized from phosphoribose diphosphate through a series of three 
successive reactions (Meniche et al., 2008): (i) transfer of phosphoribose diphosphate to 
decaprenyl phosphate to form decaprenylphosphoryl-5-phosphoribose, (ii) removal of the 5′ 
phosphate in order to give decaprenylphosphoryl-D-ribose (DPR, Figure 5), and (iii) 
epimerization of DPR into DPA, which likely occurs via a sequential oxidation-reduction 
mechanism involving an intermediate (DPX, Figure 5), which is a product of DPR oxidation 
and a precursor of DPA. Although not unambiguously identified, DPX is most probably a 
decaprenylphosphoryl-2-keto-β-D-erythro-pentofuranose (Figure 5). 
 
Fig. 5. The enzymatic reaction catalyzed by decaprenylphosphoryl--D-ribose 2’ 
epimerase (composed by DprE1 and DprE2) is reported. DPR indicates 
decaprenylphosphoryl-D-ribose, while DPX is the intermediate decaprenylphospho-2-
ketofuranose and DPA the decaprenylphosphoryl-D-arabinose. 
The epimerization reaction is reported in Figure 5. It is catalyzed by the decaprenyl-
phospho-ribose 2’-epimerase, a heteromeric enzyme composed of two types of polypeptides 
encoded by the Rv3790 (dprE1) and Rv3791 (dprE2) genes, respectively (Wolucka, 2008; 
Mikusova et al., 2005). The membrane-associated enzymes DprE1 and DprE2 have been 
suggested to act as decaprenylphosphoryl-β-D-ribose oxidase and decaprenylphosphoryl-D-
2-keto erythro pentose reductase, respectively (Makarov et al., 2009). It is noteworthy that 
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for epimerase activity, a simultaneous expression of both polypeptides is required 
(Mikusova et al., 2005).   
Little is known about the decaprenyl-phosphoribose 2’-epimerase. The DprE1 protein 
contains a FAD-binding N-terminal and a C-terminal D-arabinono-1,4-lactone oxidase-like 
enzyme domains (Wolucka, 2008). What is evident now, however, is that the decaprenyl-
phosphoribose 2’-epimerase enzyme is a very important and authentic validated target for 
antitubercular drugs, being the target for at least three different classes of antitubercular 
drugs, namely benzothiazinones, dinitrobenzamides, and benzoquinoxalines whose lead 
compound is VI-9376, a molecule structurally related to benzothiazinones (Makarov et al., 
2009; Christophe et al., 2009; Magnet et al., 2010). 
Both the dprE1 and dprE2 genes were predicted to be essential by Himar1-based transposon 
mutagenesis in M. tuberculosis H37Rv (Sassetti et al., 2003), thus validating both enzymes as 
targets for drug development. Moreover, recently the construction of a conditional gene 
knockout strain targeting the ortholog of dprE1 in M. smegmatis, MSMEG_6382, has been 
reported (Crellin et al., 2011). Disruption of the chromosomal copy of MSMEG_6382 was 
only possible in the presence of a plasmid-encoded copy of MSMEG_6382. Curing of this 
‘‘rescue’’ plasmid from the bacterial population resulted in a cessation of growth, further 
demonstrating gene essentiality. This study provides the first direct experimental evidence 
for the essentiality of DprE1 in mycobacteria. Moreover, the essentiality of DprE1 in M. 
smegmatis, combined with its conservation in all sequenced mycobacterial genomes, 
suggests that decaprenylphosphoryl-D-arabinose synthesis is essential in all mycobacteria 
(Crellin et al., 2011). Overall, this study further validates DprE1 as a promising target for 
new anti-mycobacterial drugs. 
Although many potential drug targets have been already identified, greater efforts are 
required in target validation to properly show their essentiality for bacterial growth and 
survival (Williams and Duncan, 2007). A rational antibiotic design strategy should aim to 
identify targets for which the resistance mechanism has the most negative effect on fitness, 
as in the case of the DprE1 enzyme. In fact, our data suggest that DprE1 is an optimal target 
also for MDR- and XDR-TB strains. The treatment of these strains is difficult if not 
impossible nowadays and could instead be defeated by a drug targeting dprE1 gene 
product. The disruption of this essential ring in the construction of the mycobacterial cell 
wall makes the pathogen weak and completely unable to survive in a hostile environment, 
such as the macrophage. Moreover, decaprenylphosphoryl-D-arabinose is the only known 
Araf donor in the biogenesis of arabinogalactan and lipoarabinomannan in mycobacteria 
and is thus an essential precursor.  
It is worth mentioning that decaprenylphosphoryl-D-arabinose is a lead molecule for the 
design of substrates’ analogs for mycobacterial arabinosyltransferases and of new inhibitors 
(Wolucka, 2008). Since 2004, the synthesis of decaprenylphosphoryl-D-arabinose analogs as 
antitubercular agents has been performed. Even if these molecules inhibit mycobacterial 
growth, their effect was not satisfactory (Centrone and Lowary, 2004). Other efforts have 
been made by researchers in order to interfere with arabinogalactan and lipoarabinomannan 
biosynthesis. Indeed, in 2009 Pathak and co-workers reported the synthesis of modified Araf 
disaccharides as substrates and inhibitors of M. tuberculosis arabinosyltransferases (Pathak et 
al., 2009). Furthermore, Ayers and collaborators synthesized β-arabino glycosyl sulfones, 
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mimicking decaprenylphosphoryl-D-arabinose, as possible inhibitors of cell wall 
biosynthesis in mycobacteria (Ayers et al., 2009). They demonstrated a low to moderate anti-
mycobacterial activity, which is strongly dependent on alkyl chain length.  
In summary, DprE1, as well as its orthologs, are not only optimal targets for 
benzothiazinones, dinitrobenzamides and the lastly described benzoquinoxalines (Makarov 
et al., 2009; Christophe et al., 2009; Magnet et al., 2010), but also promising targets for the 
discovery of new molecules in treating infections caused by M. tuberculosis, Mycobacterium 
leprae, Nocardia spp., Rhodococcus spp., and Corynebacterium spp. 
At present, a fundamental goal is the production of large amounts of soluble DprE1 protein 
in order to develop an enzymatic assay suitable for high throughput screenings and to solve 
the DprE1 structure to design new molecules affecting the arabinogalactan biosynthesis.  
5. Conclusion 
The inexorable rise in cases of tuberculosis worldwide highlights the need for new drugs 
and, in particular, for those that can shorten the duration of treatment. Recently, two new 
promising antitubercular drugs were developed (Makarov et al., 2009; Christophe et al., 
2009). Both these drugs have the same cellular target, the DprE1 of M. tuberculosis (Manina 
et al., 2010b). The preclinical development program of benzothiazinone lead (BTZ043) has 
already begun and this class of drugs is very promising. 
Moreover, another class of antitubercular drugs has been shown to have DprE1 as target, the 
benzoquinoxalines (Magnet et al., 2010).  
This highlights the vulnerability of DprE1 and its importance as an antitubercular target.  
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